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We have investigated whether urokinase-type plasminogen activator (u-PA) is present in the mouse in vivo 
as the proenzyme or as the active enzyme. u-PA in extracts of various murine tissues was of a one-polypep- 
tide chain form with an electrophoretic mobility indistinguishable from purified proenzyme (pro-u-PA), as 
demonstrated by SDS-polyacrylamide gel electrophoresis under recucing conditions followed by immuno- 
blotting. No 2-chain u-PA was detected in any of the extracts (detection limit 10% of that of one-chain 
u-PA). In bladder urine more than half of the u-PA was of the one-chain form. Together with previous 
immunocytochemical studies of the normal murine tissues and studies of the Lewis lung carcinoma, the pre- 
sent results indicate that in these tissues the one-chain proenzyme is the predominant form of u-PA in intra- 
cellular stores and for the first time demonstrates that at least in some cases the one-chain form constitutes 
a sizeable fraction of the u-AP in extracellular fluids in the intact organism. 
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1. INTRODUCTION 
Plasminogen activators catalyse the conversion 
of the inactive proenzyme plasminogen to the ac- 
tive protease plasmin, which in turn can degrade 
most proteins. Plasminogen is present in many ex- 
tracellular body fluids and cellular release of 
plasminogen activators constitutes a means of 
generating localized extracellular proteolysis. Two 
types of vertebrate plasminogen activators can be 
distinguished based on h4, values, immunological 
reactivity, enzymatic properties, and distribution 
in the intact organism, namely tissue-type (t-PA) 
and urokinase-type (u-PA). Both are serine pro- 
teases, of -70 and -50 kDa, respectively. They 
seem to take part in different biological processes, 
Abbreviations: u-PA, urokinase-type plasminogen ac- 
tivator; t-PA, tissue-type plasminogen activator; TBS-T, 
0.05 M Tris-HCl (pH 7.4), 0.15 M NaCl, 1% (w/v) 
Triton X-100; SDS-PAGE, SDS-polyacrylamide gel 
electrophoresis 
t-PA being a key enzyme in thrombolysis, and u- 
PA among other functions being implicated in 
degradation of the extracellular matrix during 
tissue degradation in normal and pathological con- 
ditions, including cancer (reviews, [l-5]). Recent- 
ly, the amino acid sequences of human u-PA [6] 
and human t-PA [7] were determined, 
demonstrating that these two enzymes are products 
of different genes. 
We have previously reported that u-PA is re- 
leased as an inactive proenzyme (pro-u-PA) from 
murine sarcoma virus-transformed fibroblasts 
cultured under serum-free conditions. The proen- 
zyme was a one-polypeptide chain protein. By 
limited proteolysis with plasmin it was converted 
to active u-PA consisting of two polypeptide 
chains held together by one or more disulphide 
bonds [8]. Similar findings have been reported for 
u-PA released from cultured human cells of 
neoplastic origin [9- 111. SDS-PAGE under reduc- 
ing conditions followed by immunoblotting allows 
discrimination between one- and two-chain u-PA 
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in tissue extracts, and we have shown that extracts 
of Lewis lung carcinoma tissue contained one- 
chain u-PA but no detectable amounts of two- 
chain u-PA [12]. We now report that only one- 
chain u-PA is detectable in extracts of kidney, 
placenta, vas deferens, oxyntic mucosa of the 
stomach and the lung, which by im- 
munocytochemical methods have been found to 
contain cells producing u-PA [ 131. In addition, we 
report that more than half of the u-PA present in 
murine bladder urine was of the one-chain form, 
thus demonstrating unequivocally the extracellular 
presence of this form in the intact organism. 
2. MATERIALS AND METHODS 
Female and male 6-10 week old BALB/c mice 
were perfused and tissues extracted with 0.1 M 
Tris-HCl (pH 8.1), 0.5% Triton X-100 (lO,&mg 
tissue, wet wt) as described [13,141. Urine was col- 
lected directly from the bladder of diethylether- 
anaesthetized mice. u-PA enzyme activity was 
determined in the 1251-fibrin plate assay, using in- 
hibition with anti-u-PA IgG to determine the part 
of total plasminogen activator activity that was 
due to u-PA [ 131. One unit of murine u-PA is 
defined in [15]. After SDS-PAGE proteins were 
transferred electrophoretically (10 V, 50 mA, 
24 h) to nitrocellulose paper (Millipore GSWP 
00010, 0.22 pm) in a buffer containing 0.125 M 
Tris, 0.2 M glycine (pH 8.6), 20% (v/v) methanol 
and 0.1% (w/v) SDS [16,17]. After transfer, the 
paper was air-dried. The dried paper could be 
stored at room temperature for several months 
without loss of immunoreactivity. Longitudinal 
lanes were cut out of the paper. The lanes were 
fixed with paraformaldehyde, incubated with 
human serum albumin in order to block remaining 
binding sites and incubated with anti-u-PA IgG 
(purified by affinity chromatography), non- 
immune IgG, or anti-u-PA preabsorbed with an 
excess of highly purified pro-u-PA [ 131. In order to 
detect the sites of antigen-antibody reaction, the 
lanes were incubated for 45 min at room temper- 
ature with horseradish peroxidase-conjugated Pro- 
tein A (Amersham), diluted 200-fold in 0.05 M 
Tris-HCl (pH 7.4), 0.15 M NaCl, 1% (w/v) Triton 
X-100 (TBS-T) with 0.25% (w/v) bovine serum 
albumin, followed by washing with TBS-T (5 X 
5 min) and 0.05 M Tris-HCl (pH 7.6) (2 x 5 min). 
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The peroxidase activity was demonstrated with 
diaminobenzidine-Hz02 [ 131. After the peroxidase 
reaction, the lanes were rinsed shortly in 0.05 M 
Tris-HCl (pH 7.6), and photographed immediately 
afterwards. All other materials and procedures 
were as described [8,13,15,18,19]. 
3. RESULTS 
In SDS-PAGE under non-reducing conditions, 
both murine pro-u-PA and active u-PA migrate as 
single bands of -48 kDa; under reducing condi- 
tions, the pro-u-PA migrates at -48 kDa, while ac- 
tive u-PA migrates as two bands of -29 and 
-18 kDa, respectively [8]. The immunoblotting 
procedure allowed the detection of as little as 10 U 
of purified pro-u-PA or active u-PA under non- 
reducing conditions. Under reducing conditions, 
the detection limit for pro-u-PA and the -29-kDa 
band of active u-PA was 25 U, while the -18-kDa 
band was visible only if more than 400 U was ap- 
plied to the gel. Application of equal amounts of 
pro-u-PA and active u-PA to the gels always 
resulted in bands of approx. equal intensity at -48 
and -29 kDa, respectively. 
One-chain u-PA was found in extracts of 
kidney, placenta, vas deferens, oxyntic mucosa of 
the stomach and lung, while no two-chain u-PA 
was detected in any of these extracts (fig.1). This 
was true even when the gels were loaded with up to 
75 ~1 of any of the extracts, corresponding to max- 
imally 600 U of activator (not shown). These find- 
ings indicated that in all tissues less than 10% of 
the total u-PA content was present in the two- 
chain form. 
The same conclusion was reached when the stan- 
dard extraction buffer was replaced by 0.075 M 
potassium acetate, 0.1 M L-arginine (pH 4.2), 
0.3 M NaCl, 10 mM EDTA, 0.25% (w/v) Triton 
X-100 [20] or by 0.1 M Tris-HCl (pH 7.4), 0.1% 
(w/v) SDS. There was no loss of either pro-u-PA 
or active u-PA during the extraction procedure, as 
judged by immunoblotting controls, in which 
purified preparations were added to the buffer 
before extraction (not shown). 
Immunoblotting analysis of bladder urine 
showed that more than half of the u-PA immuno- 
reactivity migrated as one-chain u-PA in SDS- 
PAGE under reducing conditions. Immunoblot- 
ting after SDS-PAGE under non-reducing condi- 
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Fig.1. Immunoblotting analysis of u-PA in extracts of murine tissues. The following samples were separated by SDS- 
PAGE under educing conditions: (1) 100 U purified active u-PA; (2) 100 U purified pro-u-PA; extracts of (3) kidney 
(25 $1, 200 ,ug protein, 195 U u-PA); (4) piacenta (day 19 of pregnancy, 25 ~1, 150 ,ug protein, 65 U u-PA); (5) vas 
deferens (25 ~1, 75 yg protein, 70 U u-PA); (6) stomach (oxyntic mucosa, 50 ~1, 250 fig protein, 60 U u-PA); (7) lung 
(5OJ, 250 ,ug protein, 200 U u-PA). Following SDS-PAGE proteins were transferred electrophoretically to
nitrocellulose paper. The paper was stained immunochemically using either 5 gg/ml anti-u-PA IgG (A), 5 fig/ml anti-u- 
PA IgG preabsorbed with 42 kU/ml purified pro-u-PA (B), or 5 pg/ml nonimmune IgG {C). For all samples, the 
controls with preabsorbed anti-u-PA IgG and nonimmune IgG were negative. For clarity, only control stainings of 1-3 
are shown. The localization of i&marker proteins [6] and the estimated M, of the immunochemically stained band are 
indicated. 
tions showed both -4% and -2%kDa forms of 
u-PA (fig.2). We have previously reported that the 
latter form has plasminogen activator activity+ It is 
probably a conversion product of the -48-kDa 
form [l&19], corresponding to the -36-kDa, low 
molecular mass form of human u-PA 1211. 
4. DISCUSSION 
The present findings demonstrate that more 
than 90% of the u-PA in extracts of a number of 
murine tissues is present in a one-chain form with 
a mobility in SDS-PAGE that is indistinguishable 
from that of pro-u-PA, and therefore presumably 
is identical to the inactive proenzyme form. In the 
tissues investigated in the present study, most u- 
PA immunoreactivity appeared to be located in- 
tracellularly as evaluated by immunoc~ochemistry 
with light microscopy. In kidneys and vas 
deferens, it was apparently located in secretion 
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Fig.2. Immunoblotting analysis of u-PA in murine bladder urine. The following samples were separated by SDS-PAGE: 
(1) 100 U purified active U-PA; (2) 100 U purified pro-u-PA; (3) 2.5,4(100 U) bladder urine. Experimental conditions 
were as described in the legend to fig.1 except that the SDS-PAGE was performed under both non-reducing (A) and 
reducing (B) conditions. Staining was performed with anti-u-PA IgG. Controls with nonimmune IgG or with anti-u-PA 
IgG preabsorbed with pro-u-PA were negative (not shown). Note that purified active u-PA migrates slightly slower than 
pro-u-PA in SDS-PAGE under non-reducing conditions. 
granules in tubular and stereociliated cells, respec- 
tively [ 131. This indicates that the one-chain proen- 
zyme is the predominant form of u-PA in the in- 
tracellular stores. 
We recently reported that more than 80% of the 
u-PA in extracts of Lewis lung carcinoma [12] was 
present in the one-chain form. In this carcinoma 
most of the u-PA immunoreactivity appeared to be 
located extracellularly or associated with the cell 
membrane [12]. These results suggested that one- 
chain pro-u-PA was present extracellularly in 
Lewis lung carcinoma. The finding here that more 
than half of the u-PA in bladder urine is present as 
the one-chain form unequivocally shows that this 
form can occur extracellularly under in vivo condi- 
tions, in agreement with findings in vitro [8- 111. 
Trace amounts of one-chain u-PA were found in 
freshly voided murine urine (not shown). This lat- 
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ter finding is in agreement with a previous study in 
which a one-chain form of u-PA was purified from 
human urine with a yield of 3% of the total 
plasminogen activator activity [22]. The 
mechanism of pro-u-PA activation in urine as well 
as the physiological role of this activation remains 
to be elucidated. 
The present findings together with the fact that 
plasminogen is present in many extracellular body 
fluids [23-281 make it likely that pro-u-PA and 
plasminogen often coexist in such fluids, and that 
as yet unknown initiating factors are crucial to the 
regulation of the cascade reaction that leads to 
plasmin-mediated extracellular proteolysis by this 
pathway. It may be speculated that such initiating 
factors are different in different biological pro- 
cesses that involve u-PA catalysed plasminogen ac- 
tivation, and that such initiators therefore con- 
tribute to the functional diversity of u-PA that is 
suggested by its occurrence in a variety of different 
cell types in the intact organism [12,13]. 
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